Altimmune (ALT) Consolidated Net Income (2010 - 2026)
Altimmune's (ALT) quarterly Consolidated Net Income came in at -$22.6 million in Q1 2026, down 15.26% year-on-year from -$26.6 million in Q1 2025, and down 129.74% on a QoQ basis from $75.9 million in Q4 2025.
Altimmune (ALT) Consolidated Net Income (2010 - 2026) Analysis & Trends
Altimmune (ALT) has 17 years of Consolidated Net Income data on file, last reported at -$22.6 million in Q1 2026.
- On a quarterly basis, Consolidated Net Income fell 15.26% year-over-year to -$22.6 million in Q1 2026; TTM through Mar 2026 was $12.1 million, a 113.44% increase from a year earlier, with the FY2025 full-year figure at $15.1 million, up 120.13% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$22.6 million, down from $75.9 million in the prior quarter.
- Over the last five years, Consolidated Net Income for ALT reached as high as $75.9 million in Q4 2025 and fell as low as -$31.6 million in Q4 2023.
- Historically, Consolidated Net Income has averaged -$15.6 million across 5 years, with a median of -$20.7 million in 2023.
- Across the five-year window, Consolidated Net Income sank 228.09% in 2023 and surged 427.24% in 2025, its largest moves.
- Year by year, Consolidated Net Income stood at -$9.6 million in 2022, then sank by 228.09% to -$31.6 million in 2023, then increased by 26.74% to -$23.2 million in 2024, then jumped by 427.24% to $75.9 million in 2025, then tumbled by 129.74% to -$22.6 million in 2026.
- Per Business Quant data, the three most recent Consolidated Net Income figures were -$22.6 million in Q1 2026, $75.9 million in Q4 2025, and -$19.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Altimmune | 7.96 Mn | 7.96 Mn | - | -22.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.56 Mn |
| Dec 31, 2025 | 75.86 Mn |
| Sep 30, 2025 | -19.01 Mn |
| Jun 30, 2025 | -22.15 Mn |
| Mar 31, 2025 | -19.58 Mn |
| Dec 31, 2024 | -23.18 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -24.39 Mn |
| Dec 31, 2023 | -31.64 Mn |
| Sep 30, 2023 | -20.67 Mn |
| Jun 30, 2023 | -16.90 Mn |
| Mar 31, 2023 | -20.19 Mn |
| Dec 31, 2022 | -9.64 Mn |
| Sep 30, 2022 | -23.52 Mn |
| Jun 30, 2022 | -20.13 Mn |
| Mar 31, 2022 | -19.58 Mn |
| Dec 31, 2021 | -5.38 Mn |
| Sep 30, 2021 | -33.51 Mn |
| Jun 30, 2021 | -24.83 Mn |